GLUE Monte Rosa

Monte Rosa Therapeutics Reports Positive GFORCE-1 Phase 1 Topline for MRT-8102 in ASCVD Risk Subjects

MRT-8102 achieved robust NEK7 degradation and normalized multiple key ASCVD pathogenic drivers (DAMPs, IL-1β, hsCRP, fibrinogen, Lp(a)) to healthy-volunteer levels in obese subjects with elevated CVD risk. The asset was safe and well-tolerated with no SAEs or increased infection risk. This topline outcome informs dose selection and enables planned Phase 2 starts in coronary artery disease (GFORCE-2, H1 2027), gout (GEMINI-1, Q4 2026/Q1 2027), and hidradenitis suppurativa (GALAXY-1, H1 2027).